Brief: Abbvie Says Phase 3 Studies Show Continued Repigmentation With Rinvoq Through Week 76
01/10/2026 17:11
BRIEF-Abbvie Says Phase 3 Studies Show Continued Repigmentation With Rinvoq Through Week 76 Oct 1 (Reuters) - AbbVie Inc. ABBV.N:
ABBVIE - PHASE 3 STUDIES SHOW CONTINUED REPIGMENTATION WITH RINVOQ THROUGH WEEK 76
ABBVIE - RINVOQ PLUS NB-UVB SHOWS HIGHER REPIGMENTATION THAN RINVOQ ALONE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AbbVie
See all newsBrief: Abbvie Reaches Agreement With The Pan-Canadian Pharmaceutical Alliance (Pcpa) For Elahere® In Platinum-Resistant Ovarian Cancer
Eli Lilly hits record high as healthcare stocks rally
Nvidia-backed Iambic Therapeutics tumbles below IPO price
Factbox: Pharma sector doubles down on AI to slash costs, timelines
Brief: Abbvie Says Risankizumab In Ulcerative Colitis Shows Clinical Remission Rates Of 54.0%-73.1% At Week 96